公开(公告)号：EP2938347A4

公开(公告)日：2016-08-10

申请号：EP13869473

申请日：2013-12-30

申请人： HADASIT MED RES SERVICE ,  B G NEGEV TECHNOLOGIES & APPLIC LTD AT BEN GURION UNIVERSITY

发明人： COHEN SMADAR ,  ILAN YARON ,  SHTEYER EYAL ,  BEN-YA ACOV AMI

IPC分类号： A61K31/734 ,  A61K31/738 ,  A61P1/16

CPC分类号： A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

摘要： Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than −25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10−8 cm2/millisecond, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease, liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

摘要翻译： 组合物包含藻酸盐的，钠离子源和载体（例如，药学上可接受的载体），这是由藻酸盐链的缔合减少表征并因此，通过中的至少一个：（i）的ζ电位弱于-25 毫伏，以0.5％（W / v）在载体的藻酸盐的浓度; 和（ⅱ）至少10-8厘米2 /毫秒的扩散系数，以0.5％的浓度（重量/体积）在载体藻酸盐，是游离缺失盘。 所以游离缺失盘是所述组合物的用途和利用用于治疗炎性肠疾病，肝损伤，疾病和病症中，用于治疗医学病症可治疗由肝毒性药剂和用于减少或预防肝功能损害，包括由肝毒性肝损伤的组合物的方法 剂。

公开(公告)号：EP2938348A4

公开(公告)日：2016-07-27

申请号：EP13869503

申请日：2013-12-30

申请人： HADASIT MED RES SERVICE ,  B G NEGEV TECHNOLOGIES & APPLIC LTD AT BEN GURION UNIVERSITY

发明人： COHEN SMADAR ,  ILAN YARON ,  SHTEYER EYAL ,  BEN-YA ACOV AMI

IPC分类号： A61K31/734 ,  A61P1/16 ,  A61P29/00

CPC分类号： A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

摘要： Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than −25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10−8 cm2/millisecond, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease, liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

摘要翻译： 包含藻酸盐，钠离子源和载体（例如药学上可接受的载体）的组合物，其特征在于藻酸盐链的缔合减少，因此通过以下至少一种：（i）弱于-25的ζ电位 mV，载体中浓度为0.5％（w / v）藻酸盐; 和（ii）载体中浓度为0.5％（w / v）藻酸盐的至少10-8cm 2 /毫秒的扩散系数。 还公开了利用组合物治疗炎症性肠病，肝损伤，疾病和病症的组合物和方法的用途，用于治疗由肝毒性剂治疗的医学病症，以及用于减少或预防肝损伤，包括由肝毒性引起的肝损伤 剂。